Briviact (brivaracetam) Disease Interactions
There are 4 disease interactions with Briviact (brivaracetam):
Antiepileptics (applies to Briviact) suicidal tendency
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Depression, Psychosis
Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs across multiple indications in either monotherapy or adjunctive therapy for a median treatment duration of 12 weeks (up to a maximum of 24 weeks) showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo. The estimated rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% for 16,029 placebo-treated patients, representing an increase of approximately one case for every 530 patients treated. There were four suicides in AED-treated patients and none in placebo-treated patients, although the number is too small to establish any causal relationship. The increased risk of suicidal thoughts or behavior was observed as early as one week after starting AEDs and persisted for the duration of treatment assessed. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed. Therapy with AEDs should be administered cautiously in patients with depression or other psychiatric disorders. The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior. For clinically significant or persistent symptoms, a dosage reduction or treatment withdrawal should be considered. If patients have symptoms of suicidal ideation or behavior, treatment should be discontinued.
Brivaracetam (applies to Briviact) bronchospasm/angioedema.
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Asthma
Bronchospasm and angioedema have been reported in patients taking brivaracetam and a hypersensitivity reaction to this agent could predispose patients at risk. Caution is recommended when using brivaracetam in patients predisposed to bronchospasm and angioedema.
Brivaracetam (applies to Briviact) hepatic dysfunction
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Brivaracetam is primarily metabolized by hydrolysis in the liver. A pharmacokinetic study in adult subjects with hepatic cirrhosis, Child-Pugh grades A, B, and C, showed 50%, 57%, and 59% increases in brivaracetam exposure, respectively, compared to matched healthy controls. Because of increases in brivaracetam exposure, dosage adjustment is recommended for all stages of hepatic impairment as per manufacturer recommendation. Care and close monitoring is recommended when using this agent in patients with liver disease.
Brivaracetam (applies to Briviact) renal impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
No dose adjustments are needed for patients with impaired renal function. The use of brivaracetam is not recommended in patients with end-stage renal disease undergoing dialysis as there are no data in this patient population.
Briviact (brivaracetam) drug interactions
There are 281 drug interactions with Briviact (brivaracetam)
Briviact (brivaracetam) alcohol/food interactions
There is 1 alcohol/food interaction with Briviact (brivaracetam)
More about Briviact (brivaracetam)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- 31 Reviews
- Drug class: pyrrolidine anticonvulsants
- FDA Approval History
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.